Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
Want to see ACRS full AI Analyst Report?
ACRS Stock Chart & Stats
$4.25
-$0.03(-1.20%)
At close: 4:00 PM EST
$4.25
-$0.03(-1.20%)
Day’s Range― - ―
52-Week Range$1.34 - $5.15
Previous CloseN/A
Volume227.82K
Average Volume (3M)1.11M
Market Cap
$628.49M
Enterprise Value$506.35M
Total Cash (Recent Filing)$105.42M
Total Debt (Recent Filing)$1.99M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Aug 12, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding139,663,680
10 Day Avg. Volume1,094,755
30 Day Avg. Volume1,106,653
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue60.52
Enterprise Value/Gross Profit79.28
Enterprise Value/Ebitda-7.17
Forecast
1Y Price Target
$10.67Price Target Upside150.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$5.71M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained very high gross margins indicate that, if Aclaris scales revenue or outlicenses assets, a large portion of incremental sales could flow to the bottom line. This structural cost advantage supports margin sustainability and potential profitability as clinical assets mature.
Low LeverageMinimal debt reduces fixed financial obligations and preserves strategic flexibility for clinical-stage programs. Low leverage lowers bankruptcy risk and makes the company better positioned to access equity or partnership capital without being constrained by debt covenants.
Pipeline De-risking: ATI-052 Phase 1aPositive first-in-human results for ATI-052 materially de-risk the bispecific program, improving clinical and commercial optionality. Best-in-class PK and infrequent dosing support competitive positioning, enhance partner/licensing prospects, and raise the long-term asset value of the pipeline.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow implies ongoing reliance on external capital to sustain development programs. This structural cash burn pressures runway, forces recurring financings, and constrains investment flexibility until meaningful revenue or partnership cash arrives.
Small, Volatile Revenue BaseA very small and inconsistent revenue base cannot cover fixed operating costs, leaving the business dependent on financing or milestone payments. This weak revenue foundation raises execution risk and lengthens the time to achieve self-sustaining operations.
Reliance On Equity Financing / Dilution RiskFrequent recourse to equity financing to fund development dilutes existing holders and can erode returns. Structural dependence on equity markets increases vulnerability to funding conditions and may force less favorable terms, impacting long-term shareholder value.
Aclaris Therapeutics News
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $1.34 and its highest was $5.15 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $628.49M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 51 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on May 12, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.008.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 139,663,680 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went down -1.414%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in ACRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aclaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (150.98% Upside)
$10.67 (150.98% Upside)
Hedge Fund Trend
Increased
By 7.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.39%
12-Months-Change
Fundamentals
Return on Equity
-55.89%
Trailing 12-Months
Asset Growth
0.32%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
ACRS Stock 12 Month Forecast
Average Price Target
$10.67
▲(150.98% Upside)
Technical Analysis
Ownership Overview
12.39% Insiders
7.41% Mutual Funds
48.90% Other Institutional Investors
20.49% Public Companies and
Individual Investors